Listing 3 - Actual negotiations

Indication:

Seizures associated with Tuberous Sclerosis Complex (TSC)

Indication:

Dravet Syndrome (DS)

Indication:

Lennox-Gastaut Syndrome (LGS)

Indication:

Multiple Indications

Indication:

Multiple Indications

Indication:

Non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC

Indication:

For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor

Indication:

In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c-ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC

Indication:

Multiple Indications

Indication:

Thrombosis and cardiovascular conditions (prevention or treatment)